Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366
文献类型：期刊论文
| 作者 | Liu, Xuemei2; Deng, Decheng3; Meng, Jian1; Hu, Haitang3; Zhuang, Quankun2; Zhou, Xue3; Fu, Long3; Fan, Binke2; Xu, Xueting2; Huang, Qin3 |
| 刊名 | FRONTIERS IN PHARMACOLOGY
 |
| 出版日期 | 2025-11-10 |
| 卷号 | 16页码:11 |
| 关键词 | JP-1366 P-CABs mass balance study radioactivity drug metabolism pharmacokinetics |
| DOI | 10.3389/fphar.2025.1701581 |
| 通讯作者 | Huang, Qin(Huangqin01@livzon.cn) ; Chen, Xiaoyan(xychen@simm.ac.cn) ; Hou, Fang(houf@gobroadhealthcare.com) |
| 英文摘要 | Introduction JP-1366 (zastaprazan), a novel potassium-competitive acid blocker (P-CAB), was approved in South Korea in 2024 for treating erosive gastroesophageal reflux disease (GERD). This mass balance study characterized the pharmacokinetics, metabolism, excretion, and safety profile of JP-1366 in humans, supporting its further clinical development in China.Methods Six healthy Chinese male adults received a single oral dose of 20 mg (100 mu Ci) [14C]JP-1366 under fasting conditions in this open-label Phase I study. Serial samples of blood, plasma, urine, and feces were collected and analyzed to determine Pharmacokinetic parameters, total radioactive recovery, metabolic fate, and excretion routes.Results JP-1366 was rapidly absorbed, with median Tmax values of 0.875 h observed for both the parent drug and total radioactivity in human plasma. The mean plasma elimination half-life (t1/2) was approximately 28 h for JP-1366-related material. Furthermore, the blood-to-plasma ratio of total radioactivity ranged from 0.561 to 0.645, indicating limited distribution of drug-related material into blood cells. Within 264 h post-dose, 94.3% of the administered radioactive dose was recovered through excretion, predominantly via feces (51.9%) and urine (42.4%). JP-1366 underwent extensive metabolism in vivo, generating 57 metabolites, while the parent drug remained undetectable in excreted samples. The principal metabolic pathways involved oxidations (Phase I) and the following glucuronidation (Phase I/II). JP-1366 exhibited a favorable safety profile, with no serious adverse events reported.Conclusion JP-1366 exhibited favorable pharmacokinetic properties characterized by rapid absorption, extensive metabolism, and predominant fecal excretion of drug-related material. The principal metabolic pathways involved oxidations and the following glucuronidation.Clinical Trial Registration http://www.chinadrugtrials.org.cn/, identifier CTR20244931. |
| 资助项目 | Livzon Pharmaceutical Group Co. |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001621047700001 |
| 出版者 | FRONTIERS MEDIA SA |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/322007]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Huang, Qin; Chen, Xiaoyan; Hou, Fang |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China 2.Beijing GoBroad Hosp, Phase Clin Res Ctr 1, Beijing, Peoples R China 3.Livzon Pharmaceut Grp Co Ltd, Zhuhai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Liu, Xuemei,Deng, Decheng,Meng, Jian,et al. Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366[J]. FRONTIERS IN PHARMACOLOGY,2025,16:11. |
| APA | Liu, Xuemei.,Deng, Decheng.,Meng, Jian.,Hu, Haitang.,Zhuang, Quankun.,...&Hou, Fang.(2025).Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366.FRONTIERS IN PHARMACOLOGY,16,11. |
| MLA | Liu, Xuemei,et al."Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366".FRONTIERS IN PHARMACOLOGY 16(2025):11. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。